新型口服抗凝药的特点和临床研究  

Characteristics and clinical research of new oral anticoagulants

作　　者：周建光[1] 周颖奇[1] 

机构地区：[1]中国人民解放军第411医院神经内科,上海200081

出　　处：《临床药物治疗杂志》2013年第5期8-14,共7页Clinical Medication Journal

摘　　要：口服抗凝药在心脑血管血栓疾病的防治中发挥了重要作用,新型口服抗凝药包括直接凝血酶抑制剂达比加群,Xa因子抑制剂利伐沙班、阿哌沙班、贝曲西班和依杜沙班,无需监测、相互作用少,循证医学试验证实在术后血栓、心房颤动,以及急性冠脉综合征中疗效及安全性好于华发林、依诺肝素等,不良反应小。Oral anticoagulants play an important role in the prevention and managment of heart and cerebral thrombosis disease. New oral anticoagulants including dabigatran etexilate （direct thrombin inhibitor） and inhibition of factor Xa such as rivaroxaban, apixaban, edoxaban and betrixaban. Monitoring is not necessary and less interaction is found in these new oral anticoagulants. Evidence-based medical tests confirm that new oral anticoagulants are more safety and efficacy and less adverse reactions than warfarin and enoxaparin on postoperative blood clots, atrial fibril ation and acute coronary syndrome.

关 键 词：抗凝药 达比加群 利伐沙班 阿哌沙班 贝曲西班 依杜沙班 

分 类 号：R937.2[医药卫生—生药学] R541.75[医药卫生—药学]